3.4 Clinical characteristics and Imatinib
Cssmin
Currently, the recommended dosage of imatinib targeted therapy is 400
mg/d. The difference between the neoadjuvant treatment group (male=6;
female=3) and the adjuvant treatment group (male=4; female=5) was
evaluated at the dosage of 400 mg/d. The Cssmin of two
groups was similar (p=0.402, figure 4).
Considering no significant difference in Cssmin of
imatinib between above two group, correlation between
Cssmin and gender, age, Body Mass Index (BMI),
medication duration, primary tumor site of 18 patients receiving 400
mg/d imatinib were compared, respectively. As in figure 5, significant
difference was observed in Cssmin of imatinib between
female and male patients. The median value of women was significantly
higher than that of men (1998 ng/mL vs 1468 ng/mL, p=0.016). There was
no correlation between Cssmin and age (r=-0.028,
p=0.911), BMI (r=0.098, p=0.700), medication duration (r=-0.069,
p=0.787).